NEW YORK (GenomeWeb News) – Canadian biomarker test developer GeneNews reported today an uptick in third-quarter revenues to C$400,000 (US$382,000) from C$300,000 in the same quarter last year.

Toronto-based GeneNews attributed the revenue increase to an undisclosed collaborative research agreement; receipts from an Asian biomedical consortium; and sales of its lead product, the ColonSentry biomarker test for prognosing colon cancer risk.

GeneNews slashed its net loss by 64 percent to C$1.4 million from C$3.9 million year over year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.